Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04689152
PHASE3

Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis

Sponsor: Pharmicell Co., Ltd.

View on ClinicalTrials.gov

Summary

This phase III clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected hepatic artery.

Official title: A Multicenter, Randomized, Open-label Phase III Clinical Trial to Evaluate Efficacy and Safety of the Cellgram-LC in Patients With Alcoholic Liver Cirrhosis

Key Details

Gender

All

Age Range

20 Years - 71 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2021-03-02

Completion Date

2028-01-02

Last Updated

2024-03-21

Healthy Volunteers

No

Interventions

BIOLOGICAL

Cellgram-LC

Patients will receive single injection of Cellgram-LC(mesenchymal stem cell) hepatic artery.

Locations (11)

Soonchunhyang University Hospital

Bucheon-si, South Korea

Soonchunhyang University Hospital

Cheonan, South Korea

Gangwon National University Hospital

Chuncheon, South Korea

Hallym Univ. Medical Center

Chuncheon, South Korea

Gangneung Asan Hospital

Gangneung-si, South Korea

Eunpyeong St. Mary's Hospital

Seoul, South Korea

Korea University Anam Hospital

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Soonchunhyang University Hospital

Seoul, South Korea

Wonju Severance Christian Hospital

Wŏnju, South Korea

Yongin Severance Hospital

Yŏngin, South Korea